Open AccessDose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women
Author(s) -
Juki Ng,
Kristof Chwalisż,
David C. Carter,
Cheri E. Klein
Publication year - 2017
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2016-3845
Subject(s) - luteinizing hormone , medicine , endocrinology , placebo , hormone , follicle stimulating hormone , pharmacokinetics , dosing , hormone antagonist , adverse effect , gonadotropin , pharmacodynamics , gonadotropin releasing hormone , endocrine system , alternative medicine , pathology
Elagolix is a nonpeptide, oral gonadotropin-releasing hormone (GnRH) antagonist being developed for sex-hormone-dependent diseases in women.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom